BC
Broadwood Capital Portfolio holdings
AUM
$1.53B
This Quarter Return
-12.03%
1 Year Return
+36.91%
3 Year Return
+67.63%
5 Year Return
+132.65%
10 Year Return
+697.91%
AUM
$1.12B
AUM Growth
+$1.12B
(-16%)
Cap. Flow
-$194M
Cap. Flow
% of AUM
-17.27%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
1
Reduced
3
Closed
–
Top Buys
| 1 |
STAAR Surgical
STAA
|
$19.3M |
Top Sells
| 1 |
IMDX
Insight Molecular Diagnostics Inc. Common Stock
IMDX
|
$149M |
| 2 |
Monster Beverage
MNST
|
$43M |
| 3 |
iShares Russell 2000 ETF
IWM
|
$21.9M |
Sector Composition
| 1 | Consumer Staples | 40.02% |
| 2 | Healthcare | 37.64% |
| 3 | Industrials | 13.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Monster Beverage
MNST
$60.9B
| $450M | 40.02% | 8,501,236 -811,740 | -9% | -$43M |
|
|
2
STAAR Surgical
STAA
$1.36B
| $372M | 33.1% | 9,264,427 +481,345 | +5% | +$19.3M |
|
3
Axon Enterprise
AXON
$58.7B
| $151M | 13.45% | 760,062 | – | – |
|
|
4
iShares Russell 2000 ETF
IWM
$67B
| $100M | 8.89% | 566,000 -124,000 | -18% | -$21.9M |
|
5
Lineage Cell Therapeutics
LCTX
$267M
| $41.2M | 3.67% | 34,935,485 | – | – |
|
|
IMDX
6
Insight Molecular Diagnostics Inc. Common Stock
IMDX
$72.4M
| $7.83M | 0.7% | 2,509,066 -47,672,269 | -95% | -$149M |
|
7
Serina Therapeutics
SER
$54.5M
| $2.04M | 0.18% | 2,997,156 | – | – |
|